Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
515312
Reference Type
Journal Article
Title
Risk factors for hepatitis C recurrence after liver transplantation
Author(s)
Roche, B; Samuel, D
Year
2007
Is Peer Reviewed?
1
Journal
Journal of Viral Hepatitis
ISSN:
1352-0504
EISSN:
1365-2893
Volume
14
Page Numbers
89-96
Language
English
Abstract
Hepatitis C virus (HCV)-related end-stage liver disease is the main indication for liver transplantation performed in Europe and the United States. Recurrence of hepatitis C in the graft is universal and may lead to chronic hepatitis in most patients and to cirrhosis in 20-30%, of patients within 5-10 years of transplantation. The natural history of HCV recurrence is highly variable but leads to a lower survival rate than other recurrent liver diseases. The inummosuppressed status and several other factors have been linked with the pattern and severity of recurrence. What remains controversial are those factors associated with fibrosis progression and how these could be modified to improve outcome of recurrent hepatitis C. No single factor but a combination of several factors is associated with fibrosis progression on the graft. The major factors associated with accelerated disease recurrence include: high viral load pre- (> 10(6) IU/mL) and/or early post-transplantation (> 10(7) IU/mL at 4 months), donor older than 40-50 years, prolonged ischaemic time, cytomegalovirus coinfection, over immunosuppression and/or abrupt changes in immunosuppression, HIV coinfection, infection by genotype 1b. Cautious follow-up of the pathology of the graft is mandatory including routine biopsies and/or noninvasive monitoring of fibrosis.
Keywords
hepatitis C; immunosuppression; liver transplantation; recurrence; stellate cell activation; fibrosis progression; donor age; virus-replication; cyclosporine-a; living donor; calcineurin; inhibitors; mycophenolate-mofetil; histologic recurrence; rejection; episodes
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity